Epigenomics is currently at EUR 2.52 with a plus of more than 14.5 percent; in the course of the day so far, biotech shares have already seen a peak of EUR 2.58. The Berlin company’s stake got off to a strong start into the new week, thanks mainly to news from the USA. A new study in the Journal of the National Cancer Institute showed that Epigenomics’ Epi proColon is “the test of choice for many patients unwilling to undergo colon cancer screening with FIT or colonoscopy,” the company said.
“An annual Epi proColon test turned out to be more cost-efficient compared to Cologuard under all five analyzed modeling scenarios,” the company said on Monday. Epigenomics sees the results of previous studies confirmed. According to Jorge Garces, President and CSO of Epigenomics AG, the colon cancer test from Berlin could reduce the incidence and mortality of colon cancer just as effectively or better than other approved methods.
More about biotech stocks on 4investors: click here
At a glance – chart and news: Epigenomics